DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the SUN PHARMACEUTICAL IND L (SUNPHARMA) share price today?

SUN PHARMACEUTICAL IND L (SUNPHARMA) is trading at ₹1,932.6 on the NSE, down 0.90% on the day. Source: DocStoX.

What is the PE ratio of SUN PHARMACEUTICAL IND L?

SUN PHARMACEUTICAL IND L has a price-to-earnings (PE) ratio of 40.4 in the Healthcare sector.

What is the market capitalisation of SUN PHARMACEUTICAL IND L?

SUN PHARMACEUTICAL IND L has a market capitalisation of approximately ₹4,63,789 crore.

SUN PHARMACEUTICAL IND L

F&O

SUNPHARMA·NSE·Healthcare

₹1,932.60▼ -17.50 (-0.90%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

NIFTY 50NIFTY 100NIFTY 200

Day₹1922.50

₹1952.60

52W₹1548

₹196393%

Open

₹1948.70

High

₹1952.60

Low

₹1922.50

Prev Close

₹1950.10

Volume

24.76L

VWAP

₹1937.15

Snapshot

Key fundamentals

Market Cap

₹4.64L Cr

P/E Ratio

40.40Expensive

P/B Ratio

5.57

EPS

₹47.84

Book Value

₹348.00

ROE

16.00%Strong

ROCE

21.00%Efficient

Dividend Yield

0.83%

Debt / Equity

0.06Low

Face Value

₹1.00

52W High

₹1962.70

52W Low

₹1548.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹459

▼ 76.3%downside

Trading at ₹1,933 — 76% above our estimate

BearFair valueBull

₹390₹459₹612

/100

Business quality — Solid

Growth 41Profitability 77Efficiency 33Valuation 61

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 1/9)

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 21%)
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

16% ROE fading to 12% over ~10 yrs, on ₹348 book

₹416

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹612

Analyst target

No analyst coverage

—

Blended fair value₹459

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 21%)
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

40.4Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

16.0%Strong

Above 15% is considered healthy for Indian equities

ROCE

21.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.06Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹4.64L Cr

P/B

5.57

EPS

₹47.84

Div Yield

0.83%

What changed

Recent changes

Foreign investors-0.2% stake last quarter
Domestic institutions+0.3% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 40.4×

Growth

Steady

+10% rev CAGR

Profitability

Healthy

16.0% ROE

Financial health

Rock solid

D/E 0.06

Momentum

N/A

No technicals

Today

Trading activity

Delivery %71.6%

Turnover₹47957.22L Cr

Trades84,763

VWAP₹1937.15

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+10.0%

+11.8%

10Y

+7.5%

Profit

+10.6%

+38.3%

10Y

+7.4%

EPS

+10.6%

+31.6%

10Y

+9.7%

Profile

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 34.1%

Watch-outs

Cons

The company has delivered a poor sales growth of 11.8% over past five years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 0.19 pts; domestic institutions added 0.29 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

54%

Promoter

Promoters

54.5%0.00

Public

5.3%-0.10

FII / FPI

15.9%-0.19

DII

21.1%+0.29

Others

3.2%

Total shareholders

6,90,957-19,943 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter54.48%

FII15.93%

DII21.11%

Public5.30%

Others3.18%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

F&O